Results 1 to 10 of about 29,860 (191)

Safety of prolonged treatment with bedaquiline in programmatic conditions

ERJ Open Research, 2022
Bedaquiline is now considered a first-line medicine for treatment of rifampicin-resistant tuberculosis (RR-TB). We evaluated the safety of treatment with bedaquiline for longer than 190 days in individuals with RR-TB under programmatic conditions.
Dzmitriy Zhurkin, Elmira Gurbanova, Jonathon R. Campbell, Dick Menzies, Svetlana Setkina, Hennadz Hurevich, Varvara Solodovnikova, Dzmitry Viatushka, Alan Altraja, Alena Skrahina   +9 more
doaj   +2 more sources

Successful Translational Prediction of Bedaquiline's Phase 2a Clinical Trial Results against Tuberculosis: The Zebrafish as a New Approach Methodology. [PDF]

Clin Pharmacol Ther
Tuberculosis remains an urgent global health crisis that requires an accelerated development of novel regimens. Rodent and rabbit studies currently inform early translational predictions. However, the zebrafish (Danio rerio) embryo/larva, as a New Approach Methodology, provides an ethical, cost‐effective, and high‐throughput non‐mammalian disease model
van Lieshout B, Hanuun A, van Hasselt JGC, van Wijk RC.   +3 more
europepmc   +2 more sources

Bedaquiline reloading strategies following interruptions during daily dosing [PDF]

Antimicrobial Agents and Chemotherapy
Once-daily bedaquiline therapy is a WHO-listed alternative to thrice-weekly dosing for rifampicin-resistant tuberculosis, but, contrary to the thrice-weekly schedule, no guidance exists for treatment re-initiation after interruption.
Nienke Kikstra, Stijn W. van Beek, Gary Maartens, James C. M. Brust, Elin M. Svensson, Simon E. Koele   +5 more
doaj   +2 more sources

Adverse events in bedaquiline- and pretomanid-based regimens for drug-resistant tuberculosis from trial, implementation and pharmacovigilance studies. [PDF]

Br J Clin Pharmacol
Abstract The availability of safety data, particularly concerning adverse events (AEs) associated with the new shorter regimen for drug‐resistant tuberculosis (TB) containing a bedaquiline–pretomanid‐based regimen, is still limited. This systematic review aims to provide a comprehensive and updated analysis of AEs related to this new regimen by ...
Maria N, Larasati AL, Hamdani IY, Cho JG, Alffenaar JC.   +4 more
europepmc   +2 more sources

The First Documented Case of Congenital Drug-Resistant Tuberculosis in Indonesia: A Case Report. [PDF]

Respirol Case Rep
This case presents the first documented instance of congenital rifampicin‐resistant tuberculosis (RR‐TB) in Indonesia, where a 32‐week preterm neonate exhibited non‐specific respiratory and sepsis‐like symptoms. After clinical deterioration and the identification of maternal TB, the diagnosis of congenital RR‐TB was confirmed through various tests ...
Centauri C, Adiprabowo SF, Marsubrin PMT, Pratomo IP.   +3 more
europepmc   +2 more sources

Drug-Resistant Tuberculous Spondylitis Treated with Bedaquiline-Containing Regimens in South Korea: Two Case Reports [PDF]

Antibiotics
Background: South Korea continues to report a considerable burden of drug-resistant tuberculosis (TB). Bedaquiline-containing regimens are recommended for multidrug-resistant pulmonary TB, but evidence regarding the optimal treatment for extrapulmonary ...
Keon Young Lee, Miri Hyun, Ji Yeon Lee, Hyun ah Kim   +3 more
doaj   +2 more sources

An Interactive Pharmacokinetic‐Pharmacodynamic Framework to Evaluate Bedaquiline Dose Modifications in Adults With Tuberculosis [PDF]

CPT: Pharmacometrics & Systems Pharmacology
Bedaquiline is approved for use in a thrice‐weekly dosing schedule; simpler once‐daily dosing strategies could enable fixed‐dose combinations and improve patient adherence.
Yu‐Jou Lin, Frances Okibedi, Mats O. Karlsson, Elin M. Svensson   +3 more
doaj   +2 more sources

Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis

BMC Infectious Diseases, 2022
Background This retrospective cohort study assessed benefits and risks of bedaquiline treatment in multidrug-resistant-tuberculosis (MDR-TB) combination therapy by evaluating safety, effectiveness, drug utilization and emergence of resistance to ...
Helen Pai, Norbert Ndjeka, Lawrence Mbuagbaw, Koné Kaniga, Eileen Birmingham, Gary Mao, Lori Alquier, Kourtney Davis, Arianne Bodard, Abeda Williams, Magalie Van Tongel, Florence Thoret-Bauchet, Shaheed V. Omar, Nyasha Bakare   +13 more
doaj   +1 more source

Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis

International Journal of Infectious Diseases, 2021
Objectives: To determine the safety and efficacy of bedaquiline for Chinese patients with multidrug-resistant tuberculosis (MDR-TB) based on serum concentration monitoring and to identify factors associated with QTc prolongation occurring during ...
Jinmeng Li, Gaoyi Yang, Qingshan Cai, Yu Wang, Yingying Xu, Ruoying Zhang, Yazhen Lang, Xinjun Cai   +7 more
doaj   +1 more source

A prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Korea

BMC Infectious Diseases, 2023
Background Multidrug-resistant tuberculosis (MDR-TB) represents a major public health concern, with an ongoing need for new effective treatments. Bedaquiline is an oral diarylquinoline that has shown encouraging treatment success and culture conversion ...
Tae Sun Shim, Helen Pai, JeongHa Mok, Seung Heon Lee, Yong-Soo Kwon, Jae Chol Choi, JaeSeok Park, Eileen Birmingham, Gary Mao, Lori Alquier, Kourtney Davis, Florence Thoret-Bauchet, Ji Hyun Kim, Hyeongyeong Kim, Nyasha Bakare   +14 more
doaj   +1 more source